Claims
- 1. A compound of the Formula 1:
- 2. The compound according to claim 1 of the structure:
- 3. The compound according to claim 1 of the structure:
- 4. The compound according to claim 14, which is selected from the group consisting of:
i) 5-(3-Nitro-phenyl)-1,3-dihydro-indol-2-one; ii) 3-methyl-5-(3-nitrophenyl)-1,3-dihydroindol-2-one; iii) 5-(3-Methoxy-phenyl)-3,3-dimethyl-1,3-dihydro-indol-2-one; iv) 5-(3-Chloro-phenyl)-3,3-dimethyl-1,3-dihydro-indol-2-one; v) 3,3-Dimethyl-5-(3-nitro-phenyl)-1,3-dihydro-indol-2-one; vi) 5-(3-Chloro-phenyl)-3-ethyl-1,3-dihydro-indol-2-one; vii) 5-(3-Chloro-phenyl)-3,3-diethyl-1,3-dihydro-indol-2-one; viii) 5-(3-Chloro-phenyl)-3-methoxy-3-methyl-1,3-dihydro-indol-2-one; ix) 5-(3-Chloro-phenyl)-3-methoxy-3-prop-1-ynyl-1,3-dihydro-indol-2-one; and x) 5-(3-Chloro-phenyl)-1,3-dihydro-indol-2-one; or a pharmaceutically acceptable salt thereof.
- 5. The compound according to claim 1, which is selected from the group consisting of:
i) 3-(1′,2′-Dihydro-2′-oxospiro[cyclohexane-1,3′-[3H]indol]-5′-yl)pyridine carbonitrile; ii) 4-(1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2-thiophenecarbonitrile; iii) 5-(1′,2′-Dihydro-2′-oxospiro[cyclohexane-1,3′-[3H]indol]-5′-yl)-thiophene-3-carbonitrile; iv) 2-(1′,2′-Dihydro-2′-oxospiro[cyclohexane-1,3′-[3H]indol]-5′-yl)-thiophene-2-carbonitrile; v) 5-(1′,2′-Dihydro-2′-oxospiro[cyclohexane-1,3′-[3H]indol]-5′-yl)-3-furancarbonitrile; vi) 5-(1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-propyl-2-thiophenecarbonitrile; vii) 5-(1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1H-3-nitropyrrole-2-carbonitrile; viii) 5-(1,2-Dihydro-2-oxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-2-furancarbonitrile; and ix) 4-(1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2-furancarbonitrile; or a pharmaceutically acceptable salt thereof.
- 6. The compound according to claim 1 which is selected from the group consisting of:
i) 5′-(Pyrimidin-5-yl)-spiro[cyclohexane]-1,3′-[3H]indol-2′(1H)-one; ii) 5′-(1H-Indol-4-yl)spiro[cyclohexane-1,3′-[3H]indol]-2′(1′H)-one; iii) 5-(5-Chloro-2-thienyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-one; iv) 5-(5-Acetyl-2-thienyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-one; v) 5′-(5-Nitro-1-methyl-pyrrol-2-yl)spiro[cyclohexane-1,3′-[3H]indol]-2′(1′H)-one; (vi) 5-(2-Nitro-1H-pyrrol-3-yl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-one; (vii) 5-(5-Nitro-1H-pyrrole-2-yl)spiro[cyclopentane-1,3-[3H]indol]-2(1H)-one; and (viii) 5′-(5-Nitro-1H-pyrrol-2-yl)spiro[cyclohexane-1,3′-[3H]indol]-2′(1′H)-one; or a pharmaceutically acceptable salt thereof.
- 7. The compound according to claim 1, which is selected from the group consisting of:
i) 5-(2′-oxo-2′,3′-dihydrospiro[cyclohexane-1,3′-[3H]indol]-5′-yl)-2-thiophenecarbonitrile; ii) 4-Methyl-5-(2′-oxo-2′,3′-dihydrospiro[cyclohexane-1,3′-[3H]indol]-5′-yl)-2-thiophene carbonitrile; iii) 4-Ethyl-5-(2′-oxo-2′, 3′-dihydrospiro[cyclohexane-1,3′-[3H]indol]-5′-yl)-2-thiophenecarbonitrile; iv) 5-(2′-oxo-2′,3′-dihydrospiro[cyclohexane-1,3′-[3H]indol]-5′-yl)-2-nitro-thiophene; and v) 5′-(5-Chloro-3-methylbenzo[b]thien-2-yl)spiro[cyclohexane-1,3′-[3H]indol]-2′(1′H)-one; or a pharmaceutically acceptable salt thereof.
- 8. The compound according to claim 1, which is selected from the group consisting of:
i) 4-(1,2-Dihydro-2-oxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-2-thiophenecarbonitrile; ii) 4-Methyl-5-(2′-oxo-2′,3′-dihydrospiro[cyclopentane-1,3′-[3H]indol]-5′-yl)-2-thiophene carbonitrile; and iii) 5-(2′-oxo-2′,3′-dihydrospiro[cyclopentane-1,3′-[3H]indol]-5′-yl)-2-nitrothiophene; or a pharmaceutically acceptable salt thereof.
- 9. The compound according to claim 14, which is selected from the group consisting of:
i) 5-(3-Chloro-4-fluoro-phenyl)-3,3-dimethyl-1,3-dihydro-indol-2-one; ii) 3-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-benzonitrile; iii) 5-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl) -4-methyl thiophene -2-carbonitrile; iv) 5-(3-Chloro-5-fluoro-phenyl)-3,3-dimethyl-1,3-dihydro-indol-2-one; v) 5-(3-Fluoro-5-nitro-phenyl)-3,3-dimethyl-1,3-dihydro-indol -2-one; vi) 4-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-furan-2-carbonitrile; vii) 5-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-furan-2-carbonitrile; viii) 3-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl) -5-fluorobenzonitrile; ix) 2-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl) -2-nitro-pyrrole; x) 5-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-thiophene-2-carbonitrile; xi) 3-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl) -2-fluorobenzonitrile; and xii) 3,3-Dimethyl-5-(5-nitro-thiophene-2-yl)-1,3-dihydro-indol -2-one; or a pharmaceutically acceptable salt thereof.
- 10. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
- 11. A method of inducing contraception in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
- 12. A method of treating or preventing benign or malignant neoplastic disease, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
- 13. The method of claim 12 wherein the benign or malignant neoplastic disease is selected from the group consisting of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy; carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, pituitary, meningioma and other hormone-dependent tumors.
- 14. A compound of the Formula 1:
- 15. A compound selected from the group consisting of 2-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-pyrrole-1-carboxylic acid tert-butyl ester; 5-(1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol])-5-n-butyl-2-thiophenecarbonitrile; Nitro-5-(1,2-dihydro-2-oxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester; and 5-(1,2-dihydro-2-oxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester; or a pharmaceutically acceptable salt thereof.
- 16. A compound of the structure:
- 17. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
- 18. A method of inducing contraception in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of claim 14, or a pharmaceutically acceptable salt thereof.
- 19. A method of treating or preventing benign or malignant neoplastic disease, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of claim 14, or a pharmaceutically acceptable salt thereof.
- 20. The method of claim 19, wherein the benign or malignant neoplastic disease is selected from the group consisting of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy; carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, pituitary, meningioma and other hormone-dependent tumors.
- 21. A pharmaceutical composition comprising a compound of claim 16, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
- 22. A method of inducing contraception in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of claim 16, or a pharmaceutically acceptable salt thereof.
- 23. A method of treating or preventing benign or malignant neoplastic disease, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of claim 22, or a pharmaceutically acceptable salt thereof.
- 24. The method of claim 16, wherein the benign or malignant neoplastic disease is selected from the group consisting of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy; carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, pituitary, meningioma and other hormone-dependent tumors.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application Ser. No. 09/552,632, filed Apr. 19, 2000, which claims the benefit of the priority of US Patent Application No. 60/183,058, filed May 4, 1999, now abandoned.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60183058 |
May 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09552632 |
Apr 2000 |
US |
Child |
10014173 |
Dec 2001 |
US |